© Florida Institue for Clinical Research | Privacy Policy
Website by 
High Triglycerides (ARO-APOC3 for Severe Hypertriglyceridemia)
SHASTA-3 AROAPOC3-3003
The purpose of this study is to evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) to reduce levels in adult participants with severe hypertriglyceridemia (SHTG).
To participate in this study you must:
- Have a diagnosis of severe hypertriglyceridemia (SHTG)
- Have TG levels ≥ 500 mg/dL
- Have an HbA1C of ≤ 8.5%
- Be on standard lipid-lowering medications